Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Assets Average (2016 - 2025)

Historic Assets Average for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $478.0 million.

  • Coherus Oncology's Assets Average fell 1897.45% to $478.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478.0 million, marking a year-over-year decrease of 1897.45%. This contributed to the annual value of $539.1 million for FY2024, which is 291.0% down from last year.
  • As of Q3 2025, Coherus Oncology's Assets Average stood at $478.0 million, which was down 1897.45% from $405.3 million recorded in Q2 2025.
  • Coherus Oncology's Assets Average's 5-year high stood at $767.5 million during Q1 2021, with a 5-year trough of $405.3 million in Q2 2025.
  • In the last 5 years, Coherus Oncology's Assets Average had a median value of $569.7 million in 2022 and averaged $578.5 million.
  • In the last 5 years, Coherus Oncology's Assets Average soared by 7532.97% in 2021 and then tumbled by 4365.06% in 2025.
  • Over the past 5 years, Coherus Oncology's Assets Average (Quarter) stood at $710.5 million in 2021, then fell by 27.4% to $515.9 million in 2022, then increased by 17.6% to $606.7 million in 2023, then decreased by 21.42% to $476.8 million in 2024, then rose by 0.26% to $478.0 million in 2025.
  • Its Assets Average stands at $478.0 million for Q3 2025, versus $405.3 million for Q2 2025 and $409.8 million for Q1 2025.